The FDA on March 23, 2022, approved PLUVICTO® for the treatment of adult patients with Prostate-Specific Membrane Antigen (PSMA)-positive metastatic Castration-Resistant Prostate Cancer (mCRPC), who have been treated with Androgen Receptor (AR) pathway inhibition and taxane-based chemotherapy. PLUVICTO® is a product of Advanced Accelerator Applications USA, Inc., a Novartis company.
Bottom Ad
Advertisement
Subscribe
